Apyx Medical price target raised to $4.50 from $4 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on Apyx Medical to $4.50 from $4 and keeps an Overweight rating on the shares. Apyx reported Q2 sale that missed the firm’s estimate, but beat on the bottom-line, the analyst tells investors. While the rapid trajectory through the end of the year in management’s reiterated revenue guidance “has us a little cautious,” Piper thinks “these results are achievable,” the analyst tells investors.